Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
Glioblastomas are generally resistant to treatment with immune checkpoint inhibitors. Here the authors show that IL6 blockade, in combination with a CD40 agonist, overcomes macrophage-mediated immunosuppression and sensitizes glioblastoma to immune checkpoint blockade in preclinical models.
Guardado en:
Autores principales: | Fan Yang, Zhenqiang He, Hao Duan, Duo Zhang, Juehui Li, Huijuan Yang, Jay F. Dorsey, Wei Zou, S. Ali Nabavizadeh, Stephen J. Bagley, Kalil Abdullah, Steven Brem, Lin Zhang, Xiaowei Xu, Katelyn T. Byrne, Robert H. Vonderheide, Yanqing Gong, Yi Fan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b5c127f1aaa240298e7d6cf386dcde4f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma
por: Tianrun Liu, et al.
Publicado: (2018) -
Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α
por: Qirui Wang, et al.
Publicado: (2018) -
Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment
por: S. V. Timofeeva, et al.
Publicado: (2021) -
Drug and disease signature integration identifies synergistic combinations in glioblastoma
por: Vasileios Stathias, et al.
Publicado: (2018) -
Synergistic Effects of Acoustics-based Therapy and Immunotherapy in Cancer Treatment
por: Yuheng Bao, et al.
Publicado: (2021)